OncoCyte Co. (NYSEAMERICAN:OCX) has been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.60.
Separately, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of OncoCyte in a research report on Wednesday, June 16th.
OCX traded down $0.14 on Thursday, reaching $5.43. The company’s stock had a trading volume of 2,793 shares, compared to its average volume of 512,897. OncoCyte has a 1 year low of $1.15 and a 1 year high of $6.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.49 and a current ratio of 6.49. The firm has a market cap of $496.63 million, a PE ratio of -14.47 and a beta of 1.89. The firm has a 50 day moving average of $2.27.
A number of hedge funds have recently made changes to their positions in OCX. Pura Vida Investments LLC increased its stake in OncoCyte by 94.6% during the 1st quarter. Pura Vida Investments LLC now owns 12,223,953 shares of the biotechnology company’s stock valued at $63,442,000 after buying an additional 5,941,130 shares during the period. BlackRock Inc. boosted its stake in OncoCyte by 41.9% during the 1st quarter. BlackRock Inc. now owns 4,968,214 shares of the biotechnology company’s stock valued at $25,784,000 after purchasing an additional 1,466,183 shares in the last quarter. Orbimed Advisors LLC bought a new position in OncoCyte during the 1st quarter valued at $10,899,000. Schonfeld Strategic Advisors LLC raised its stake in shares of OncoCyte by 1,173.8% in the 1st quarter. Schonfeld Strategic Advisors LLC now owns 1,622,824 shares of the biotechnology company’s stock worth $8,423,000 after buying an additional 1,495,424 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of OncoCyte by 50.6% in the first quarter. Geode Capital Management LLC now owns 1,141,078 shares of the biotechnology company’s stock valued at $5,922,000 after buying an additional 383,317 shares during the period. Institutional investors own 60.64% of the company’s stock.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Read More: Strike Price
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.